CoChat

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

Open access

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Abstract

Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NASH. Methods: NASH was induced in Wistar rats using a choline-deficient high-fat diet plus intraperitoneal sodium nitrite injections. First, a dose-finding study was performed with 10 mg/kg and 30 mg/kg of cilofexor, focusing on histological readouts. Liver fibrosis was assessed by Picro-Sirius-Red, desmin staining and hepatic hydroxyproline content. Gene expression was determined by RT-PCR. In a subsequent hemodynamic study, rats received 30 mg/kg cilofexor with or without propranolol (25 mg/kg). Portal pressure, systemic hemodynamics and splanchnic blood flow were measured. Results: Cilofexor dose-dependently induced FXR target genes shp, cyp7a1 and fgf15 in hepatic and ileal tissues, paralleled by a dose-dependent reduction in liver fibrosis area (Picro-Sirius-Red) of −41% (10 mg/kg) and −69% (30 mg/kg), respectively. The 30 mg/kg cilofexor dose significantly reduced hepatic hydroxyproline content (−41%), expression of col1a1 (−37%) and pdgfr-β (−36%), as well as desmin area (−42%) in NASH rats. Importantly, cilofexor decreased portal pressure (11.9 ± 2.1 vs. 8.9 ± 2.2 mmHg; p = 0.020) without affecting splanchnic blood-flow or systemic hemodynamics. The addition of propranolol to cilofexor additionally reduced splanchnic inflow (−28%) but also mean arterial pressure (−25%) and heart rate (−37%). Conclusion: The non-steroidal FXR agonist cilofexor decreased portal hypertension and reduced liver fibrosis in NASH rats. While cilofexor seems to primarily decrease sinusoidal resistance in cirrhotic portal hypertension, the combination with propranolol additionally reduced mesenteric hyperperfusion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines9010060

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design and treatment groups. The NASH model was induced by choline-deficient high-fat diet and injection of NaNO2 3×/week. Initially, a 10-week long dose-finding study was performed with three groups of 7 rats each. The animals received placebo treatment, 10 mg/kg or 30 mg/kg of cilofexor (CILO), respectively, from weeks 4–10. In a subsequent, 14-weeks-long study, four NASH groups (n = 7–9) received placebo, 30 mg/kg cilofexor, 25 mg/kg propranolol or a combination of the latter two compounds (Combo) from weeks 4–14 to investigate effects on hepatic hemodynamics.
Figure 1 Study design and treatment groups. The NASH model was induced by choline-deficient high-fat diet and injection of NaNO2 3×/week. Initially, a 10-week long dose-finding study was performed with three groups of 7 rats each. The animals received placebo treatment, 10 mg/kg or 30 mg/kg of cilofexor (CILO), respectively, from weeks 4–10. In a subsequent, 14-weeks-long study, four NASH groups (n = 7–9) received placebo, 30 mg/kg cilofexor, 25 mg/kg propranolol or a combination of the latter two compounds (Combo) from weeks 4–14 to investigate effects on hepatic hemodynamics.CC BY · PubMed Central
Figure 2 Cilofexor exerts dose-dependent anti-fibrotic properties. (a) The anti-fibrotic effects of FXR agonism with cilofexor (CILO) correlate with a dose-dependent decrease in Picro-Sirius red-stained area of liver sections. (b) Similarly, hepatic hydroxyproline content was significantly reduced in cilofexor-treated rats. In line with this, expression of (c) col1a1 and (d) pdgf-β are lowered by FXR agonism. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NASH (10-week model); two-sided unpaired t-test; n = 7 per group.
Figure 2 Cilofexor exerts dose-dependent anti-fibrotic properties. (a) The anti-fibrotic effects of FXR agonism with cilofexor (CILO) correlate with a dose-dependent decrease in Picro-Sirius red-stained area of liver sections. (b) Similarly, hepatic hydroxyproline content was significantly reduced in cilofexor-treated rats. In line with this, expression of (c) col1a1 and (d) pdgf-β are lowered by FXR agonism. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NASH (10-week model); two-sided unpaired t-test; n = 7 per group.CC BY · PubMed Central
Figure 3 Cilofexor decreases liver fibrosis and hepatic stellate cell activation. (a) In the prolonged NASH model, the decrease of Picro-Sirius red area in cilofexor (CILO) treated rats was confirmed. (b) In NASH rats receiving cilofexor, hepatic col1a1 expression was nearly halved by cilofexor treatment and also (c) a trend towards reduced timp1 expression was notable. (d) Desmin, a marker of hepatic stellate cell activation, was detected using immunohistochemistry. In cilofexor-treated animals, a significant reduction of desmin area was evident. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NASH (14-week model); two-sided unpaired t-test; n = 7–9 per group.
Figure 3 Cilofexor decreases liver fibrosis and hepatic stellate cell activation. (a) In the prolonged NASH model, the decrease of Picro-Sirius red area in cilofexor (CILO) treated rats was confirmed. (b) In NASH rats receiving cilofexor, hepatic col1a1 expression was nearly halved by cilofexor treatment and also (c) a trend towards reduced timp1 expression was notable. (d) Desmin, a marker of hepatic stellate cell activation, was detected using immunohistochemistry. In cilofexor-treated animals, a significant reduction of desmin area was evident. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NASH (14-week model); two-sided unpaired t-test; n = 7–9 per group.CC BY · PubMed Central
Figure 4 Effects on systemic and hepatic hemodynamics after treatment with cilofexor ± propranolol. (a) Mean arterial pressure was decreased in NASH rats and further reduced by treatment with propranolol. Cilofexor (CILO) caused no change in mean arterial pressure. (b) Heart rate remained unchanged in NASH animals and also after treatment with cilofexor, whereas propranolol (PROP) decelerated the heart significantly. (c) Portal pressure was significantly increased in NASH rats. Cilofexor decreased portal pressure alone and in combination with propranolol (COMBO). However, in NASH rats receiving solely propranolol, only a trend towards decreased portal pressure was observed. (d) Superior mesenteric blood flow (SMABF) was increased in NASH animals, and this was not changed by cilofexor. Propranolol treatment reduced SMABF to mean values comparable to the NASH-diseased control group. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NASH (14-week model); two-sided unpaired t-test; n = 7–9 per group.
Figure 4 Effects on systemic and hepatic hemodynamics after treatment with cilofexor ± propranolol. (a) Mean arterial pressure was decreased in NASH rats and further reduced by treatment with propranolol. Cilofexor (CILO) caused no change in mean arterial pressure. (b) Heart rate remained unchanged in NASH animals and also after treatment with cilofexor, whereas propranolol (PROP) decelerated the heart significantly. (c) Portal pressure was significantly increased in NASH rats. Cilofexor decreased portal pressure alone and in combination with propranolol (COMBO). However, in NASH rats receiving solely propranolol, only a trend towards decreased portal pressure was observed. (d) Superior mesenteric blood flow (SMABF) was increased in NASH animals, and this was not changed by cilofexor. Propranolol treatment reduced SMABF to mean values comparable to the NASH-diseased control group. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. NASH (14-week model); two-sided unpaired t-test; n = 7–9 per group.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 4

  1. Kirby, 2016, Evaluation of the Safety and Pharmacokinetic Effects of the Oral, Non-Steroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers, Hepatology, 64, 574A
  2. Liu, 2018, FXR Agonist GS-9674 Decreases Hepatic Fibrosis in a Mouse Model of Advanced Fibrosis Due to Nash, Hepatology, 68, 1009A
  3. Younossi, 2019, Patient-reported outcomes (PROs) in patients with primary sclerosing cholangitis (PSC) during treatment with cilofexor (GS-9674), Hepatology, 70, 805A
  4. Kowdley, 2019, The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): A phase 2, randomized, placebo-controlled trial, Hepatology, 70, 31A

Cited by

See all 72

Metadata

Authors
Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., Watkins, W. J., Trauner, M., Breckenridge, D. G., Kremoser, C., & Reiberger, T.
Affiliations
  • Medical University of Vienna (AT)
  • Phenex Pharmaceuticals (Germany) (DE)
  • Gilead Sciences (United States) (US)
  • Synovo (Germany) (DE)
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria
  • Austrian Academy of Sciences (AT)
Corresponding author
Reiberger, Thomas
Venue
Biomedicines
Publisher
MDPI AG
Published
2021-01-09
Volume
9
Issue
1
Pages
60
ISSN
2227-9059 (ISSN-L)
OpenAlex
W3120249619
Cited by
70
References
29
Citations by year
2026: 5 · 2025: 11 · 2024: 15 · 2023: 16 · 2022: 11 · 2021: 11
FWCI
9.55
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
This research was funded by Gilead Sciences and Phenex Pharmaceuticals (GS9674)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
farnesoid X receptor agonist, nonalcoholic steatohepatitis, portal hypertension, liver fibrosis, propranolol, choline-deficient high-fat diet, sodium nitrite, hepatic hydroxyproline, splanchnic circulation, hepatic hemodynamics, FGFR1, CYP7A1, COL1A1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. https://app.cochat.ai/papers/10.3390/biomedicines9010060
The paper
Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., Watkins, W. J., Trauner, M., Breckenridge, D. G., Kremoser, C., & Reiberger, T. (2021). The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines. https://doi.org/10.3390/biomedicines9010060

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.